Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.

Also called NCT01763905

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 307 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01763905
  • EudraCT 2012-001364-30
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong SAR China, Netherlands, Poland, South Africa, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01763905. Randomized; quadruple masking; primary purpose treatment. Start 2013-01-24 (actual); primary completion 2013-11-19 (actual). Results posted on 2015-12-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Acronym
GAUSS-2
Condition
Hyperlipidemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Placebo to Evolocumab
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Placebo to Ezetimibe
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01763905
Content hash
098500c5070b95470756ea9149a37937f6a9d1aac3945426fbb72c87ee26f83d